Kornimate/medical-research-clean huggingface dataset:
effect of rectal misoprostol in reducing intra-operative blood loss during myomectomy

Conditions: Blood Loss, Surgical; Uterine Myoma

Summary: a total of 200 women for elective abdominal myomectomy were randomly allocated into two groups. 100 women in experimental group were administered 400ug misoprostol (2 tablets of prosotec®) through the rectal route prior to surgery and 100 were in control group, in which no drug was administered.

after getting approval from hospital's ethical committee, patients eligible for the study were recruited in the study according to the selection criteria. before surgery, after taking informed written consent, patient's detailed history including demographics, parity \& bmi was recorded. uterine size was assessed by bimanual pelvic examination. patients undergoing myomectomy were randomly divided into 2 groups using lottery method. in experimental group misoprostol 400ug was administered per rectally prior to surgery. in control group, no drug was administered. the surgical procedural elements, the surgeon or surgeons performing the procedure and the use of antibiotics as well as anesthetic agents was standardized to remove any bias. intraoperative blood loss was recorded by a single trained doctor and calculated using visual scale for the abdominal sponges and chest swabs/gauzes used during surgery and blood collected in suction bottle.

Eligibility criteria:
inclusion criteria: 1. asa physical status class i-ii 2. intramural or subserosal fibroids - diagnosed on ultrasound 3. candidates for elective abdominal myomectomy exclusion criteria: 1. pre-operative hemoglobin \< 10 g/dl 2. patient who received danazol or gnrh analogues before surgery 3. no other systemic or metabolic disease
chemotherapy in treating patients with chronic lymphocytic leukemia

Conditions: Leukemia

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: phase i/ii trial to study the effectiveness of cc-1088 in treating patients who have chronic lymphocytic leukemia that has not responded to previous therapy.

objectives: i. determine the toxicity of cc-1088 in patients with refractory, progressive, b-cell chronic lymphocytic leukemia. ii. determine the response rate to this treatment in these patients. outline: patients receive oral cc-1088 three times a day for 28 days. treatment continues in the absence of disease progression or unacceptable toxicity. projected accrual: a total of 11-20 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically or cytologically confirmed refractory, progressive, b-cell chronic lymphocytic leukemia failed prior first line therapy of chlorambucil or fludarabine (or their equivalent) progressive disease as defined by at least one of the following: greater than 50% increase in the sum of the products of at least 2 lymph nodes on two consecutive determinations 2 weeks apart (at least one lymph node must be greater than 2 cm) appearance of new palpable lymph nodes at least a 50% increase in size of previously palpable liver or spleen appearance of palpable hepatomegaly or splenomegaly not previously present at least a 50% increase in the absolute lymphocyte count to at least 5,000/mm3 transformation to an aggressive histology (e.g., richter's or prolymphocytic leukemia) high risk or intermediate risk with active disease, as defined by the following: greater than 10% weight loss extreme fatigue fevers greater than 100.5 fahrenheit for greater than 2 weeks without infection night sweats splenomegaly greater than 6 cm lymphadenopathy greater than 10 cm lymphocytosis with a doubling time less than 6 months patient characteristics: age: 18 and over performance status: ecog or zubrod 0-2 life expectancy: not specified hematopoietic: see disease characteristics hepatic: bilirubin no greater than 2.5 times upper limit of normal (uln) alt and ast no greater than 2.5 times uln renal: creatinine no greater than 2.0 mg/dl other: not pregnant negative pregnancy test fertile patients must use effective contraception during and for 2 weeks after study prior concurrent therapy: biologic therapy: not specified chemotherapy: see disease characteristics endocrine therapy: not specified radiotherapy: not specified surgery: not specified

Keywords: refractory chronic lymphocytic leukemia b-cell chronic lymphocytic leukemia
application of deep-learning and ultrasound elastography in opportunistic screening of breast cancer

Conditions: Breast Cancer

Summary: as the most common cancer expected to occur all over the world, breast cancer still faces with the unsatisfied diagnostic accuracy in us imaging. s-detect is a sophisticated cad system for breast us imaging based on deep learning algorithms. e-breast is a software installed in us machines which automatically reveals tumor elastographic features. this multi-center study intends to further validate the diagnostic efficiency of s-detect and e-breast in opportunistic breast cancer screening populations in china. our hypothesis is that s-detect and e-breast can increase the diagnostic accuracy and specificity as compared to routinely us examinations by doctors.


Eligibility criteria:
inclusion criteria: * female over 18 years of age; * had breast lesions detected by ultrasound. * no clinical symptoms such as nipple discharge, while breast lesions were not palpable. * received breast surgery within one week of ultrasound examination. * agreed to participant in this study and signed informed consent. exclusion criteria: * patients who had received a biopsy of breast lesion before the ultrasound examination. * patients who were pregnant or lactating. * patients who were undergoing neoadjuvant treatment.
constipation fiber trial

Conditions: Functional Constipation in Children

Summary: this study examines the effects of dietary fiber in the treatment of functional childhood constipation.

this is a 4-week double-blind, placebo-controlled study to examine the effects of dietary fiber in treating functional childhood constipation. the addition of fiber is anticipated to allow children to have more normal stool consistency and frequency. all participants will be asked to take a snack bar twice daily and will be randomized in a 1:1:1 ratio to fiber 1, fiber 2 or placebo snack bar groups. all participants will be asked to take low-dose miralax to avoid worsening of constipation in all groups.

Eligibility criteria:
inclusion criteria: * 2-16 years of age with functional constipation as defined based on the rome iii criteria exclusion criteria: * constipation attributable to organic and anatomic causes or intake of medication * children who had previous surgery of the colon or anus * history of allergy/intolerance to components of snack bar (e.g. celiac disease)
cognitive training in parkinson's disease

Conditions: Parkinson Disease

Summary: the purpose of this research study is to determine whether cognitive training will improve cognitive and brain functions in people with parkinson's disease (pd) during activities of daily living using cognitive evaluations and magnetic resonance imaging (mri).


Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic pd * age ≥ 40 years * expected to be on a stable dopaminergic medication regimen throughout the study period exclusion criteria: * non-english speaking * pregnancy * breastfeeding * excessive alcohol consumption (\> 7 drinks per week for women, \> 14 drinks per week for men) or illicit substance use * history of a neurological disorder such as a brain tumor, stroke, central nervous system infection, multiple sclerosis, movement disorder (other than pd), or seizures * history of schizophrenia, bipolar disorder, attention deficit disorder, or obsessive-compulsive disorder * history of head injury with loss of consciousness longer than a few minutes * metallic surgical implants or traumatically implanted metallic foreign bodies * inability to lie flat for about an hour in the mri scanner * discomfort being in small, enclosed spaces * dementia at screening (montreal cognitive assessment score \< 21/30) * cognitive problems in activities of daily living suggestive of more than mild cognitive impairment (pd cognitive functional rating scale \> 4) * mild cognitive impairment according to the movement disorders society (mds) level ii comprehensive assessment criteria (\> 1.5 standard deviations below the norm in two tests in a single cognitive domain or in one test in two separate cognitive domains, with the exception that the executive domain scores can be up to 2 standard deviations below the norm) * hoehn \& yahr stage \> 3 (i.e., able to stand and walk, but not fully independent) * focal neurological findings on exam that suggest cerebral pathology other than that associated with parkinsonism * motor symptoms that could potentially introduce too much motion artifact in the imaging data (e.g., mds-unified pd rating scale resting tremor score \> 2 in limbs, head/chin tremor, or more than mild dyskinesia by history or exam)
identifying individuals at risk of glucocorticoid-induced impairment of bone disease

Conditions: Osteoporosis Secondary

Summary: previous studies have shown that there is a large inter-individual variability in the degree of bone loss during glucocorticoid treatment, and while some patients experience extensive bone loss other patients\&#39; bone mass remains stable. the aim of the study is to find a biomarker that can be used to identify individuals at risk of glucocorticoid-induced bone loss. the study will include 36 healthy volunteers, that will be randomized to receive either glucocorticoid treatment or placebo. during the study blood samples, bone marrow samples, bone tissue samples, and adipose tissue samples are taken and an oral glucose tolerance test is performed.


Eligibility criteria:
inclusion criteria: * men and women aged 18-50 years. exclusion criteria: * uncontrolled thyrotoxicosis * chronic kidney disease (egfr \<30) * known cushing's syndrome * previous gastric bypass and/or known ongoing malabsorption * severe covid-19 in the last 3 month (defined as needing dexamethasone treatment) * use of oral or inhaled glucocorticoids within the past year * menopause (defined as 1 year without menstrual bleeding) * pregnancy (defined as elevated hcg) * ongoing infection * allergy to prednisolone or one of the excipients * systematic fungal infections * vaccination with living or weaken viral or bacterial vaccines in patient who or immunocompromised. in these cases, prednisolone treatment should not be administered two weeks before and after vaccination * not able to provide informed consent (e.g., dementia, not able to understand danish).
multi-colored placido disk viability

Conditions: Dry Eye; Sjogren's Disease; Healthy

Summary: the purpose of this study is to show that the multi-colored placido disk set-up can get reliable data over long time periods.


Eligibility criteria:
inclusion criteria: * subjects must have clinically diagnosed dry eye or sjörgren's syndrome. * good general health (defined by medication use that has not changed within the last month and the absence of medical conditions that are deemed confounding to the data as determined by the pi) * ability to give informed consent * willing to spend time for the study; approximately 30 minutes for a visit * either gender * any racial or ethnic origin exclusion criteria: * use of any prescription ocular medication (such as but not limited to, glaucoma medications and restasis) used within 14 days of the screening visit or started prior to the measurement visit(s). * current eye disease, infection or inflammation that affects the surface of the eye such as, but not limited to blepharitis and ocular allergy. * past eye surgery, such as, but not limited to, refractive surgery. subjects who have had cataract surgery less than one year ago.

Keywords: volunteers
effect of propolis administration for dysmenorrhea in endometriosis patient with levonorgestrel implant therapy

Conditions: Endometriosis; Dysmenorrhea

Summary: the goal of this clinical trial is to investigate the effect of propolis administration on dysmenorrhea in endometriosis patient. the main questions it aims to answer are: * does the propolis administration reduce symptoms of dysmenorrhea in endometriosis? * does the propolis administration reduce the amount of oxidative stress biomarkers in endometriosis? * does the propolis administration reduce the amount of inflammatory biomarkers in endometriosis? participants will be given an intervention in the form of propolis at a dose of 1 drop per 10 kilogram of body weight per administration, twice a day. there will be a control group that will be given an intervention in the form of a placebo containing 70% caramel alcohol dye solution.


Eligibility criteria:
inclusion criteria: * women aged 20-49 years and already menstruating with complaints of menstrual pain referred to the obstetrics and gynecology polyclinic for lng implant placement * willing to have lng implant installed after receiving explanation about implants * not receiving hormonal treatment for endometriosis within the last 3 months * can receive drops (propolis) during the study exclusion criteria: * impaired liver function, degenerative diseases (dm, hypertension and cardiovascular disease), benign tumors, cancer * pregnancy and breastfeeding * hypersensitivity to levonogestrel * thromboembolic disease * experiencing bleeding for unknown reasons * history of allergies to honey and its processed products * currently taking supplements/drugs that are not included in the standard management of endometriosis patients at rscm * have consumed propolis before * received hormonal treatment within the last 3 months

Keywords: levonorgestrel implant propolis oxidative stress
interactive digital technology to assess and improve cognitive dysfunction in patients with systemic lupus erythematosus

Conditions: Lupus Erythematosus, Systemic

Summary: the purpose of this study is to evaluate whether a short interactive video game device is associated with performance on standard measures of attention and problem solving in patients with systemic lupus erythematosus(sle). the study is also designed to see if playing the video game for four weeks improves attention and problem solving in patients with sle.


Eligibility criteria:
inclusion criteria: * diagnosis of sle exclusion criteria: * major neurological problems (head trauma, degenerative vascular or metabolic disorder; neoplasm or toxic exposure) prior to sle * major psychiatric disorder prior to sle * major substance abuse * pregnant * major motor impairment * high sle disease activity * history of learning disability

Keywords: lupus sle cognition cognitive assessment videogames
oral and non-insulin injected hypoglycemic therapy utilization patterns

Conditions: Diabetes Mellitus, Type 2

Summary: this protocol is for a series of descriptive analyses conducted within a cohort of patients using linagliptin, other dipeptidyl peptidase-4 (dpp-4) inhibitors, and other oral and non-insulin injected hypoglycemic medications between may 2011 and july 2012. understanding 1) the existing utilization patterns for linagliptin, sitagliptin, saxagliptin, and other oral and non-insulin injected hypoglycemic agents and (2) the differences in utilization patterns between these agents will help with the design, analysis and interpretation of comparative effectiveness and safety studies of linagliptin, other dpp-4 inhibitors, and other agents. the study will provide an overview of existing utilization patterns for linagliptin, other dipeptidyl peptidase-4 (dpp-4) inhibitors, other oral and non-insulin injected hypoglycemic agents, in order to detect potential selective prescribing patterns that might lead to channeling bias.


Eligibility criteria:
inclusion criteria: * diagnosis of type 2 diabetes mellitus * a dispensing of an oral or non-insulin injected hypoglycemic medication between may 2011 and june 2012 * at least 6 months enrolment in the database preceding the date of the first dispensing exclusion criteria: * age \< 18 * missing or ambiguous age or sex information * at least one diagnosis of type 1 diabetes mellitus or secondary diabetes
live lung donor retrospective study

Conditions: Lung Transplantation

Summary: the use of live donors for solid organ transplantation has increased the number of available organs for those waiting for a transplant. donation of an organ may have significant effects on a donor's health. this study will determine the baseline characteristics, early postoperative morbidity, and long-term survival for participants who underwent donor lobectomy between 1993 and 2006.

as the number of patients requiring organ transplants continues to increase, the number of organs available from deceased donors cannot meet demands. beginning in the early 1990s, organs from living donors became a widely-available option, increasing the number of available organs for transplant. however, because organ donation has the potential to adversely affect a living donor's health, long-term studies to determine the effect of donation on these donors are needed. the purpose of this study is to determine the mortality, the early postoperative morbidity, and the occurrence of end stage lung disease for participants who underwent donor lobectomy between 1993 and 2006. participants in this study will have had donor lobectomy at the university of southern california in los angeles or the washington university medical center and barnes-jewish hospital in st. louis. there will be no study visits for retrospective cohort study. investigators will collect data from existing medical records and databases.

Eligibility criteria:
inclusion criteria: * had living donor lobectomy at one of the two participating study centers, the university of southern california and the washington university medical center between 1993 and 2006 (inclusive)

Keywords: living donor lung transplant end stage lung disease
expanded access for tnb-383b in a subject with relapsed/refractory multiple myeloma

Conditions: Multiple Myeloma

Summary: this is a single patient protocol for tnb-383b in a subject with relapsed/refractory multiple myeloma (mm) who is not a candidate for treatment regimens known to provide clinical benefit in mm.


Eligibility criteria:
inclusion criteria: * adequate bone marrow function * egfr ≥ 30 ml/min * total bilirubin ≤ 1.5 × upper limit of normal (uln) * serum calcium (corrected for albumin) at or below the uln range exclusion criteria: * candidate for treatment regimens known to provide clinical benefit in mm * active infection requiring parenteral anti-infective treatment * any medical or psychiatric condition which in the opinion of the investigator or teneobio medical monitor places the subject at an unacceptably high risk for toxicities, could interfere with successful or safe delivery of therapy, or could interfere with evaluation of the investigational product or interpretation of subject safety
risk factors for pulmonary hypertension of the newborn

Conditions: Persistent Fetal Circulation Syndrome; Lung Diseases

Summary: to conduct a multicenter case-control study of persistent pulmonary hypertension of the newborn (pphn) in relation to maternal exposure to smoking and non-steroidal anti-inflammatory drugs (nsaids). also, to assess other potential antenatal risk factors and collect and store buccal cell specimens for future analyses.

background: persistent pulmonary hypertension of the newborn (pphn), previously called persistent fetal circulation, is a birth defect affecting approximately 1 in 1250 liveborn term infants; even with complex and high-risk interventions, pphn results in substantial mortality and morbidity. this defect results from the inappropriate muscularization of fetal pulmonary vessels, and experimental and human evidence consistently suggests that maternal cigarette smoking and antenatal exposure to nsaids, particularly aspirin or ibuprofen, may play a role in the etiology of this condition. because these exposures are quite prevalent (e.g., ibuprofen is currently taken in the first trimester or later in pregnancy by 15 percent and 3.2 percent of women, respectively), testing these hypotheses is of considerable public health importance. design narrative: the multicenter study had a case-control design. there were 560 case infants with pphn and four controls per case (2240). all controls were drawn from the birth hospitals of cases; half the controls had malformations other than pphn, and half had normal formations. cases and controls were identified within five months of birth at 88 birth and tertiary hospitals in the areas surrounding boston, philadelphia, and toronto. mothers of subjects were interviewed by telephone within six months of delivery; a standardized questionnaire inquired in detail about demographic factors; reproductive, medical, and pregnancy illness histories; medication use (including a detailed focus on use of over-the-counter analgesic/antipyretic medications), smoking, and nutrition. because of emerging genetic research suggesting an effect of nsaids on pathways possibly related to the etiology of pphn, buccal swabs were also collected and stored for future analyses. exposure prevalences were compared between mothers of cases and controls and relative risks were estimated, controlling for potential confounding factors. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria